Please assess the completion status of the following clinical trial:

Trial Title: A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria MEI-401 Alone:~* Diagnosis of relapsed/refractory CLL and/or relapsed/refractory SLL or FL~* No prior therapy with PI3Kd inhibitors~* No prior therapy with Bruton tyrosine kinase (BTK) inhibitors unless the subject was intolerant of BTK therapy or subject had disease progression~* Subjects with CLL/SLL must have prior treatment with BTK inhibitor and must have had progression or recurrence while on treatment of within 12 mos from BTK treatment~* Subject must have failed at least 1 prior systemic therapy~* QT-interval corrected according to Fridericia's formula (QTcF) ≤ 450 milliseconds (ms)~* Left ventricular ejection fraction \> 50%~* For subjects, except those with CLL, must have at least one bi-dimensionally measurable nodal lesion \>1.5 cm, as defined by Lugano Classification~* Willingness to participate in collection of pharmacokinetic samples~* A negative serum pregnancy test within 14 days of study Day 0, for females of childbearing potential~Inclusion Criteria ME-401 in Combination with Rituximab~* Diagnosis of relapsed/refractory CLL SLL or FL, MZL, DLBCL and high-grade B-cell lymphoma. Subjects must meet the following criteria for relapsed or refractory disease:~* No prior therapy with PI3Kδ inhibitors~* No prior therapy with Bruton tyrosine kinase (BTK) inhibitors unless the subject was intolerant of BTK therapy or subject had disease progression~* Subjects with CLL, SLL, FL, and MZL must have a failure of at least 1 prior systemic therapy and be considered by the investigator a candidate for therapy with a rituximab-based regimen; subjects with DLBCL and high-grade B-cell lymphoma must have a failure of at least 2 prior therapies.~* QT-interval corrected according to Fridericia's formula (QTcF) ≤450 milliseconds (ms)~* Left ventricular ejection fraction \> 50%~* For subjects, except those with CLL, must have at least one bi-dimensionally measurable nodal lesion \>1.5 cm, as defined by Lugano Classification~* Willingness to participate in collection of pharmacokinetic samples~* A negative serum pregnancy test within 14 days of study Day 0 for females of childbearing potential~Inclusion Criteria ME-401 in Combination with Zanubrutinib~* Diagnosis of relapsed/refractory CLL or histologically-confirmed relapsed/refractory SLL or FL, MZL, MCL, DLBCL NOS (germinal center B-cell type or activated B-cell type)~* No prior therapy with PI3Kδ inhibitors~* No prior therapy with BTK inhibitors~* Subjects with CLL, SLL, FL, MCL, and MZL must have a failure of at least 1 prior systemic therapy, require treatment in the opinion of the investigator, and be considered by the investigator a candidate for therapy subjects with DLBCL and high-grade B-cell lymphoma must have a failure of at least 2 prior therapies~* For subjects with SLL, FL, MZL, MCL, DLBCL: At least one bi dimensionally measurable nodal lesion \> 1.5 cm in its longest diameter by CT scan or MRI~* QT-interval corrected according to Fridericia's formula (QTcF) ≤ 450 milliseconds (msec)~* Left ventricular ejection fraction \> 50% as measured by echocardiogram or multigated acquisition (MUGA) scan~* Willingness to participate in collection of pharmacokinetic samples~* For females of childbearing potential, a negative serum pregnancy test within 14 days of study Day 0~Exclusion Criteria:~* Known histological transformation from CLL to an aggressive lymphoma~* Uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia~* Subjects who have tested positive for hepatitis B surface antigen and/or hepatitis B core antibody~* Positive for hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) antibody~* Ongoing drug-induced pneumonitis~* History of clinically significant cardiovascular abnormalities~* History of severe bleeding disorders (ME-401 plus zanubrutinib arm only)~* Known central nervous system (CNS) hemorrhage or stroke within 6 months prior to start of study drugs (ME-401 plus zanubrutinib arm only)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ME-401 Alone (Type: EXPERIMENTAL): This arm is an open-label, dose escalation study to determine the safety, efficacy and pharmacokinetics of ME-401 along with the mBED, MTD, and DLTs. There are 4 planned cohorts which may enroll up to 61 subjects.
- ME-401 in Combination with Rituximab (Type: EXPERIMENTAL): The second arm is an open label study to evaluate the safety, efficacy, and pharmacokinetics of ME-401 in combination with rituximab in subjects with various B-cell malignancies. There are two planned cohorts which may enroll up to 30 subjects.
- ME-401 in Combination with Zanubrutinib (Type: EXPERIMENTAL): The third arm is an open label study evaluating the safety, efficacy, MTD, DLT and pharmacokinetics of ME-401 in combination with zanubrutinib in subjects with various B-cell malignancies. This arm will include 2 stages: a safety evaluation stage (cohort of 6-12 subjects) and a disease-specific expansion cohort stage (up to 74 subjects).

Based on this trial design, predict the completion outcome and termination type (if applicable).